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Fungi are ever changing their secondary metabolites profile in order to adapt to 
their environment. Previously characterized fungal cultures were re-analyzed with the 
intention of re-isolating scaled up quantities of metabolites of interest. However, in doing 
so there were several instances where fungal secondary metabolites were isolated that 
were not previously observed. The biological activities of the isolated secondary 
metabolites were evaluated using a variety of bioassays. Three compounds that were not 
previously isolated were characterized and added to our compound library. Re-isolation 
and re-analysis of fungal secondary metabolites can lead to the discovery of unsought yet 
interesting changes in secondary metabolite profile and biological activity. 
To take advantage of fungi’s ability to adapt to their environment, our lab has 
grown fungi in co-culturing experiments in hopes of activating silent biosynthetic gene 
clusters thus diversifying secondary metabolite production. The most common fungus 
utilized in these experiments has been Xylaria flabelliformis (formerly known as Xylaria 
cubensis) due to its production of the fungistatic compound and FDA approved drug, 
griseofulvin. In this study, two other Xylaria spp. are analyzed in comparison to Xylaria 
flabelliformis to determine variation in griseofulvin production among the strains and 
over time. Characterizing griseofulvin production by various Xylaria spp. leads to 
intentionality in future co-culturing experimental design, in that the optimal Xylaria sp. 
can be selected. 
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CHAPTER I 
INTRODUCTION 
 
 
1.1 Re-Isolation of Fungal Secondary Metabolites 
Fungi have the ability to biosynthesize a variety of secondary metabolites, such as 
mycotoxins, pigments, and antimicrobials. Re-isolation allows us to re-analyze 
previously characterized secondary metabolite profiles. In this re-analysis new analogues 
and different biological activities can be discovered. Re-isolation and re-analysis of fungi 
should be done to isolate the previously characterized secondary metabolites as well as 
the newly present compounds because they are potentially advantageous.1 Despite 
compound library curation, many previously isolated compounds are not available for 
new bioassay testing.  
1.2 Co-Culturing 
Fungi have the extraordinary ability to survive in an assortment of environments, 
including soil, plants and human tissues.2 They are able to survive in these environments 
by overcoming competition in various ways, such as sporulation, stress recovery, rapid 
growth and the use and nullification of inhibitors.3 It has been shown that fungi are only 
producing a fraction of their potential secondary metabolites when grown under standard 
laboratory conditions.4-6 A variety of biosynthetic gene clusters, that are not associated  
with known compounds, have been discovered and classified as silent biosynthetic gene 
2 
clusters. Co-culturing is a means to taking advantage of competitive traits by provoking a 
stress response which could in turn activate silent biosynthetic gene clusters. Thus, co-
culturing has the potential to diversify secondary metabolite biosynthesis in fungi. 
Changes in the secondary metabolite profile due to co-culturing can be monitored in situ 
via the droplet-liquid microjunction-surface sampling probe (droplet probe)7. 
1.3 Secondary Metabolites Produced by Xylaria spp. 
Griseofulvin (Figure 1a) was first discovered in 1939 in London, and today is 
commonly used for its antifungal properties as an FDA-approved drug.8-11 Since then, it 
has been determined that Xylaria sp. predominantly produce the secondary metabolites 
griseofulvin and dechlorogriseofulvin (Figure 1b). For example, Xylaria flabelliformis 
(previously known as Xylaria cubensis) is commonly found in nature as an endophyte 
(endosymbiotic) and decomposer (saprobic) and biosynthesizes the secondary 
metabolites griseofulvin and dechlorogriseofulvin.12 The production of griseofulvin has 
helped Xylaria sp. survive and thrive in various environments because of griseofulvin’s 
fungistatic properties, meaning that it inhibits fungal growth rather than killing competing 
fungi.4 
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Figure 1. (a) Griseofulvin Structure with Absolute Stereochemistry 
(b) Dechlorogriseofulvin Structure with Absolute Stereochemistry 
 
 
Griseofulvin’s fungistatic properties have led to various co-culturing studies 
based on the hypothesis that by inducing stress on another fungus the secondary 
metabolite production would change due to the two species interacting.4, 6 Fungi are 
biological organisms and present an array of biological variance both morphologically 
and chemically. In this study, the varying production of griseofulvin and 
dechlorogriseofulvin is related to the morphological variation, which can be used in 
future studies to design co-culturing experiments. 
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CHAPTER II 
RE-ISOLATION OF FUNGAL SECONDARY METABOLITES 
 
 
2.1 Experimental 
2.1.1 Fungal Culture Production 
G-strain fungal cultures are maintained on Potato Dextrose Agar (PDA; Difco) 
media and transferred periodically. To begin a new fungal culture, an agar plug with 
mycelium is transferred to Yeast Extract Soy Peptone Dextrose (YESD) broth. This seed 
culture is then incubated for three days at room temperature with agitation (~100 rpm). 
Then, the seed culture is transferred to 250 mL Erlenmeyer flasks containing 10 g of 
autoclaved rice and left to grow at room temperature for two weeks.  
2.1.2 Extraction and Purification 
A 1:1 methanol:chloroform mixture was added to the fermented fungal cultures, 
chopped, and shaken (~100 rpm) for at least 4 hours at room temperature. The culture 
was then vacuum filtered, and to the filtrate 1:2 chloroform:water was added. The filtrate 
was stirred and transferred to separatory funnel where the bottom layer (chloroform) was 
drawn off and evaporated to dryness under vacuum. The now de-sugared extract was 
reconstituted in 1:1:2 acetonitrile:methanol:hexane to remove the fats. The resulting 
mixture was then mixed vigorously and transferred to a separatory funnel where the 
bottom layer (1:1 acetonitrile:methanol) was collected and evaporated to dryness under 
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vacuum. The extract was then subjected to an initial chromatographic separation via 
normal phase flash chromatography on a Teledyne ISCO Combiflash Rf 200 which was 
monitored by an evaporative light scattering detector (ELSD) and photodiode array 
(PDA) detector. The semi-purified fractions from flash chromatography are then 
subjected to further purification via reverse HPLC. The HPLC separations were 
performed with an Atlantis T3 C18 preparative (5 µm; 19 mm × 250 mm) and semi-
preparative (5 µm; 10 mm × 250 mm) columns, at a flow rate of 16.9 ml/min and 4.6 
ml/min, respectively, with a Varian Prostar HPLC system equipped with a Prostar 210 
pump and a Prostar 335 PDA detector, with the collection and analysis of data using 
Galaxie Chromatography Workstation software. 
2.1.3 Identification and Characterization of Fungal Secondary Metabolites 
The structures of the secondary metabolites were identified via a suite of 
spectroscopic and spectrometric techniques. The HRESIMS data were collected on either 
a Thermo LTQ Orbitrap XL mass spectrometer or a Thermo Q Exactive Plus (Thermo 
Fisher Scientific); both equipped with an electrospray ionization source and a Waters 
Acquity UPLC (Waters Corp.) using a BEH C18 column (1.7 µm; 50 mm × 2.1 mm) set 
to a temperature of 40ºC and a flow rate of 0.3 ml/min. The mobile phase consisted of a 
linear gradient of CH3CN-H2O (both acidified with 0.1% formic acid), starting at 15% 
CH3CN and increasing linearly to 100% CH3CN over 8 minutes, with a 1.5-minute hold 
before returning to the starting conditions. The NMR data were collected using a JOEL 
ECS-400 spectrometer equipped with a JOEL normal geometry broadband Royal probe 
and 24-slot autosampler which was operated at 400 MHz for 1H and 100 MHz for 13C as 
6 
well as a JEOL ECA-500 spectrometer which was operated at 500 MHz for 1H and 125 
MHz for 13C (Both from JEOL USA, Inc.). 
2.2 Results 
Fifteen fungal strains were grown for re-isolation (Figure 2). Among these fungi, 
there were 92 secondary metabolites that were expected to be isolated based on 
secondary metabolites previously isolated from these fungal strains by our laboratory 
(Table 1). Of those 92, 19 were isolated and identified. Additionally, three compounds 
that our lab had not previously isolated were isolated and identified. In total, 22 
compounds were isolated via re-isolation (Figure 4).  
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Figure 2. Fungal Cultures (Top View) Grown on Solid Rice Media 
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Table 1. The Secondary Metabolites Pursued and Isolated with Amounts Prior to and 
Following Re-Isolation.  
 
# Strain Compound 
Amount 
before 
Amount 
after 
1 G77 
 
Antibiotic SS 19508D; SS 19508D 
C17H13O7Cl 
2.79 mg 2.79 mg 
2 G77 
 
Bisdechlorogeodin 
C17H14O7 
2.28 mg 2.28 mg 
3 G77 
 
Dihydrogeodin 
C17H14O7Cl2 
1.27 mg 1.27 mg 
4 G77 
 
Geodin 
C17H12O7Cl2 
12.24 mg 12.24 mg 
9 
5 G77 
 
Methyl 2,4-dichloroasterrate 
C18H16O8Cl2 
2.39 mg 2.39 mg 
6 G77 
 
Methyl asterrate; Trimethylosoic acid 
C18H18O8 
4.18 mg 4.18 mg 
7 G118 
 
Chaetocuprum 
C24H33NO8 
2.96 mg 2.96 mg 
8 G173 
 
3-Hydroxymethyl-6,8-dimethoxycoumarin 
C12H12O5 
7.23 mg 8.50 mg 
9 G173 
 
Pestalasin A 
C14H16O5 
0 mg 0 mg 
10 
10 G173 
 
Graphislactone A 
C16H14O6 
1.25 mg 0 mg 
11 G173 
 
Aspergillumarin A 
C14H16O4 
3.22 mg 3.22 mg 
12 G173 
 
Aspergillumarin B 
C14H18O4 
0 mg 1.75 mg 
13 G173 
 
Berkeleyacetal C 
C24H26O8 
3.81 mg 10.97 mg 
14 G173 
 
Thailandolide B 
C27H34O8 
0.23 mg 0.23 mg 
11 
15 G323 
 
Thielavin B 
C31H34O10 
0 mg 53.27 mg 
16 G323 
 
Thielavin C 
C32H36O10 
3.55 mg 3.55 mg 
17 G412 
 
Paeciloxocin A 
C21H24O6 
5.06 mg 5.06 mg 
18 G412  
Radiclonic acid 
C23H40O5 
0.34 mg 11.71 mg 
19 G412 
 
Purpactin C 
C23H24O7 
6.13 mg 6.13 mg 
12 
20 G412 
 
Tenellic acid C 
C23H26O7 
1.00 mg 1.00 mg 
21 G617 
 
Preaustinoid A 2 
C26H34O7 
* 1.24 mg 
22 G617 
 
Austin 
C27H32O9 
* 21.30 mg 
23 G617 
 
Vermistatin 
C18H16O6 
6.50 mg 6.50 mg 
13 
24 G617 
 
Penisimplicissin 
C16H14O6 
0.49 mg 0.49 mg 
25 G339 
 
Bisvertinolone 
C28H32O9 
6.26 mg 6.26 mg 
26 G339 
 
Trichodermol 
C15H22O3 
0 mg 0 mg 
27 G339 
 
Neobulgarone F 
C32H24Cl2O8 
3.51 mg 3.51 mg 
14 
28 G339 
 
Bisorbibutenolide 
C28H32O8 
2.61 mg 2.61 mg 
29 G339 
 
Neobulgarone E 
C32H24Cl2O8 
3.96 mg 3.96 mg 
30 G339 
 
Neobulgarone C 
C32H25ClO8 
1.24 mg 1.24 mg 
31 
 
G104 
 
Isosclerone 
C10H10O3 
0 mg 0 mg 
15 
32 G104 
 
(R)-7-Hydroxy-3-((S)-1-hydroxyethyl)-5-
methoxy-3,4-dimethylisobenzofuran- 1(3H)-one 
C13H16O5 
2.10 mg 2.10 mg 
33 G104 
 
(R)-3,4-Dihydro-4,8-dihydroxy-6-methoxy-4,5-
dimethyl- 3-methyleneisochromen-1-one 
C13H14O5 
27.76 mg 33.87 mg 
34 G104 
 
Clearanol C 
C13H14O4 
2.19 mg 2.19 mg 
35 G104 
 
Clearanol G 
C13H14O6 
0.27 mg 0.27 mg 
36 G104 
 
(3R,4S)-3,8-Dihydroxy-3-hydroxymethyl-6-
methoxy-4,5-dimethyl-isochroman-1-one 
C13H16O6 
3.39 mg 3.39 mg 
16 
37 G104 
 
Clearanol F 
C13H16O6 
0.37 mg 0.37 mg 
38 G104 
 
Radinaphthalenone 
C11H10O4 
0.38 mg 0.38 mg 
39 G104 
 
(4R)-3,4-Dihydro-4,6,8-trihydroxy-4,5-dimethyl-
3-methyleneisochromen-1-one 
C12H12O5 
2.92 mg 2.92 mg 
40 G324 
 
10,20-Dehydro[12,13-dehydroprolyl-2-(1,1-
dimethylallyl)tryptophyl]diketopiperazine] 
C21H21N3O2 
1.93 mg 1.93 mg 
41 G324 
 
Pannorin B 
C17H14O6 
4.25 mg 4.25 mg 
17 
42 G324 
 
12,13-Dehydroprolyl-2-(1,1-
dimethylallyltryptophyl)diketopiperazine 
C21H23N3O2 
0.56 mg 0.56 mg 
43 G324 
 
Deoxybrevianamide E 
C21H25N3O2 
0.32 mg 0.32 mg 
44 G369 
 
Dehydroisopenicillide 
C21H22O6 
* 0.88 mg 
45 G369 
 
Penicillide; Vermixocin A 
C21H24O6 
3.11 mg 14.32 mg 
46 G369 
 
Isosclerone 
C10H10O3 
0 mg 0 mg 
18 
47 G369 
 
Epolone B 
C24H32O4 
2.76 mg 2.76 mg 
48 G369 
 
Pycnidione 
C33H40O7 
1.61 mg 1.61 mg 
49 G87 
 
Greensporone A 
C19H21ClO6 
5.33 mg 10.05 mg 
50 G87 
 
8,9-Dihydrogreensporone C 
C19H26O5 
3.89 mg 3.89 mg 
51 G87 
 
Greensporone F 
C19H23ClO6 
0.40 mg 0.40 mg 
19 
52 G87 
 
Dechlorogreensporone D 
C19H24O6 
0.72 mg 0.72 mg 
53 G87 
 
Greensporone D 
C19H23ClO6 
0.28 mg 0.28 mg 
54 G87 
 
Dechlorogreensporone A 
C19H20O6 
0 mg 0 mg 
55 G87 
 
Greensporone E 
C19H23ClO6 
0 mg 0 mg 
56 G87 
 
Dechlorogreensporone F 
C19H22O6 
0 mg 0 mg 
20 
57 G87 
 
Greensporone G 
C19H24O6 
0 mg 0 mg 
58 G87 
 
Greensporone B 
C19H21ClO6 
0.10 mg 1.79 mg 
59 G87 
 
8,9-Dihydrogreensporone A 
C19H23ClO6 
0.30 mg 0.87 mg 
60 G87 
 
O-Desmethylgreensporone C 
C18H22O5 
0.26 mg 0.26 mg 
61 G377 
 
Monascuspyrone 
C19H32O5 
0 mg 1.30 mg 
21 
62 G377 
 
Monascuskaoliaone B 
C17H30O4 
0 mg 0 mg 
63 G377 
 
Monascuskaoliaone 
C17H30O3 
0 mg 0.32 mg 
64 G377 
 
Campyrone C 
C12H17NO4 
5.49 mg 5.49 mg 
65 G377 
 
Campyrone A 
C13H19NO4 
0.70 mg 0.70 mg 
66 G377 
 
Fonsecin 
C15H14O6 
0 mg 0 mg 
67 G377 
 
Carbonarone A 
C13H11NO3 
1.74 mg 1.74 mg 
22 
68 G377 
 
epi-Pestalamide A 
C18H17NO6 
3.78 mg 3.78 mg 
69 G377 
 
Asperazine 
C40H36N6O4 
0 mg 0 mg 
70 G377 
 
Fonsecin B 
C16H16O6 
0 mg 0 mg 
71 G377 
 
Nigragillin 
C13H22N2O 
0 mg 0 mg 
72 G377 
 
Nidiascin C 
C23H24N2O5 
0.54 mg 0.54 mg 
23 
73 G410 
 
(R)-5-Methylmellein 
C11H12O3 
0 mg 9.25 mg 
74 G410 
 
Chlamydospordiol 
C11H16O5 
0 mg 0 mg 
75 G410 
 
Acuminatopyrone 
C11H11NO3 
0 mg 5.42 mg 
76 G410 
 
Chlamydosporol (Mixture of diastereomers) 
C11H14O5 
0 mg 0 mg 
77 G410 
 
Biscognin B 
C11H10O4 
2.27 mg 3.04 mg 
78 G410 
 
Biscognin A 
C11H16O4 
0.77 mg 0.77 mg 
24 
79 G410 
 
(3R,4R)-cis-4-Hydroxy-5-methylmellein 
C11H12O4 
0 mg 0 mg 
80 G410 
 
Cyclo-[L-Phe-L-Leu-L-Leu-L-Leu-L-Ile] 
C33H53N5O5 
8.59 mg 8.59 mg 
81 G427 
 
Regiolone 
C10H10O3 
0.40 mg 2.75 mg 
82 
 
 
G427  
Cyclo-((S)-Pro-(S)-Leu) 
C11H18N2O2 
0 mg 0 mg 
83 G427 
 
Cyclo-(R-Pro-S-Phe) 
C14H16N2O2 
0 mg 0 mg 
25 
84 G427 
 
Cyclo-(S-Pro-S-Phe) 
C14H16N2O2 
0 mg 0 mg 
85 G427 
 
Isosclerone 
C10H10O3 
1.58 mg 1.58 mg 
86 G427 
 
Cyclo-(S-Ala-S-Phe) 
C12H14N2O2 
0 mg 0 mg 
87 G416 
 
4'-Methoxymadisone 
C12H16O5 
0 mg 1.37 mg 
88 G416 
 
Dimadisone 
C22H26O9 
0 mg 0.77 mg 
89 G416 
 
Madisone 
C11H14O5 
0 mg 9.20 mg 
26 
90 G416 
 
2'-Methoxymadisone 
C12H16O5 
0 mg 0 mg 
91 G416 
 
Dehydromadisone 
C11H12O4 
0 mg 0 mg 
92 G416 
 
Visnaginone 
C11H10O4 
0 mg 0 mg 
*Secondary metabolite was not previously isolated in the Oberlies research group. 
Amounts shown in green represent an increase in isolated material as part of this project. 
 
 
The extracts, initial liquid chromatography fractions, and pure compounds were 
tested in a variety of bioassays including for anti-cancer, anti-bacterial, and anti-amoeba 
activities.  
2.2.1 Thielavin B 
Thielavin B was first isolated in 1978 in Japan.13 In 1981, it was isolated from 
Thielavia terricola and found to have potent inhibition of prostaglandin biosynthesis. The 
concentration required for 50% inhibition of the conversion of 14C-arachidonic acid into 
prostaglandins F2 alpha plus E2 was 9 μM.14 Thielavin B was isolated from Thielavia 
terricola (Chaetomiaceae) (G323) and tested in various biological assays. It was inactive 
in anti-cancer, anti-bacterial, and anti-amoeba bioassays; however, it was active against 
27 
Staphylococcus aureus with 97.7% (±0.3) inhibition at 100 μg/mL and 61.2% (±1.4) 
inhibition at 10 μg/mL (Figure 5).  
2.2.2 Radiclonic Acid 
Radiclonic acid was isolated in Japan in 1973.15 It was found to stimulate the 
growth of Chinese cabbage seedling.16 Radiclonic acid was isolated from Penicillium 
aculeatum (Trichocomaceae) (G412) and tested in various biological assays. It was 
inactive in anti-cancer, anti-bacterial, and anti-amoeba bioassays. 
2.2.3 Regiolone 
Regiolone was first isolated in 1974 from Sclerotinia sclerotiorum and found to 
stimulate root elongation of rice seedlings at low concentrations and inhibit growth of 
shoots and roots at high concentrations.17 Regiolone was isolated from Minutisphaera 
aspera (Minutisphaeraceae) (G427) tested in various biological assays. It was inactive in 
anti-cancer, anti-bacterial, and anti-amoeba bioassays. 
2.2.4 Biscognin B 
Biscognin B was isolated in 2015 from milk thistle endophytes and the biological 
activity was not tested.18 Biscognin B was isolated from Biscogniauxia mediterranea 
(Xylariaceae) (G410) and found to be inactive in anti-cancer, anti-bacterial, and anti-
amoeba bioassay. 
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2.2.5 5-Methylmellein 
5-Methylmellein was first isolated in 1966 in Rome from Fusicoccum amygdali.19 
The HRMS data, 1H NMR,  and 13C NMR were collected and compared to the reported 
literature values (Table 2).20 5-Methylmellein was isolated from Biscogniauxia 
mediterranea (Xylariaceae) (G410) and found to be inactive in anti-cancer, anti-bacterial, 
and anti-amoeba bioassays. 
 
Table 2. 1H NMR Data for 5-Methylmellein in CDCl3 
 
Position 
δ
H
 (J, Hz) δ
C, type 
Literature20 
(300 MHz) 
Observed 
(400 MHz) 
Literature20 
(75 MHz) 
Observed 
(100 MHz) 
1 - - 170.321 170.49 
3 4.689 m 
4.68 ddq (12.61; 6.31; 2.93; 2.93; 
2.93) 
75.405 75.57 
3-CH3 1.555 d 1.51 d (6.32) 20.877 21.07 
4 
2.718 m 
2.951 dd 
2.72 dd (16.66, 11.62) 
2.94 dd (16.66, 3.36) 
31.852 32.04 
4a - - 137.019 137.19 
5 - - 124.894 125.05 
5-CH3 2.198 s 2.19 s 18.058 18.25 
6 6.817 d 6.82 d (8.53) 115.621 115.81 
7 7.291 d 7.29 d (8.53) 137.899 138.07 
8 - - 160.415 160.60 
8-OH 11.005 s 11.00 s - - 
8a - - 108.008 108.20 
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2.2.6 Acuminatopyrone 
In 1991, acuminatopyrone was isolated from Fusarium acuminatum. However, 
the initial structure (Figure 3a) was reported incorrectly21. The revised structure (Figure 
3b) of acuminatopyrone was established in 1994 by isolating the compound from two 
Fusarium spp. and characterized using NOEDIF and HETCOR NMR experiments.22 
Acuminatopyrone was isolated from Biscogniauxia mediterranea (Xylariaceae) (G410) 
and found to be inactive in anti-cancer, anti-bacterial, and anti-amoeba bioassays. 
 
 
Figure 3. Original and Revised Structures of Acuminatopyrone 
 
 
2.2.7 (R)-3,4-Dihydro-4,8-dihydroxy-6-methoxy-4,5-dimethyl-3-methyleneisochromen-1-
one 
(R)-3,4-Dihydro-4,8-dihydroxy-6-methoxy-4,5-dimethyl-3-
methyleneisochromen-1-one was first isolated in 2002 in Thailand.23 (R)-3,4-Dihydro-
4,8-dihydroxy-6-methoxy-4,5-dimethyl-3-methyleneisochromen-1-one was isolated from 
Paraphoma radicina (Phaeosphaeriaceae) (G104) and tested in a variety of bioassays; 
however, it was inactive in all of them. 
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2.2.8 Preaustinoid A 2 
Preaustinoid A 2 was first isolated in 2003 from a Penicillium sp. Preaustinoid A 
2 was isolated from G617 which has been identified as a Penicillium sp. The structure 
was elucidated using HRMS and 1H NMR data with reference to the published values 
(Table 3).24 It was found to be inactive in anti-cancer, anti-bacterial, and anti-amoeba 
bioassays.  
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Table 3. 1H (400 MHz) NMR Data for Preaustinoid A 2 in CDCl3 
 
Position Literature Values δH (J, Hz) Observed δH (J, Hz) 
1 6.04 d (12) 6.03 d (11.91) 
2 5.81 d (12) 5.80 d (11.86) 
5 1.79 dd (13; 3) 1.79 m 
6 1.49 m 
1.70 m 
1.51 s 
1.70 m 
7 1.87 ddd (13; 13; 3) 
2.24 ddd (13; 3; 3) 
1.86 ddd (12.88; 12.68; 3.63) 
2.23 ddd (13.73; 3.17; 3.17) 
9 0.65 dd (13; 3) 0.64 dd (13.36; 2.53) 
11 2.0 dd (13; 3) 
1.75 dd (13; 13) 
1.99 dd (13.21; 2.45) 
1.78 dd (9.96; 2.63) 
12 1.33 s 1.32 s 
13 1.18 s 1.16 s 
14 1.39 s 1.38 s 
15 1.42 s 1.41 s 
1’ 4.92 s 
5.45 s 
4.91 d (0.82) 
5.44 d (0.82) 
9’ 1.52 s 1.51 s 
10’ 1.37 s 1.36 s 
OCH3 3.74 s 3.73 s  
OH 3.28 s 3.23 s 
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2.2.9 Austin 
Austin was first isolated in 1976.25 Austin was isolate from a Penicillium sp. 
(G617) and found to be inactive in anti-cancer, anti-bacterial, and anti-amoeba bioassays. 
2.2.10 3-(Hydroxymethyl)-6,8-dimethoxy-2H-1-benzopyran-2-one 
3-(Hydroxymethyl)-6,8-dimethoxy-2H-1-benzopyran-2-one was first isolated in 
1990 in Canada.26 In this project, 3-(Hydroxymethyl)-6,8-dimethoxy-2H-1-benzopyran-
2-one was isolated from an unidentified freshwater fungus (G173). It was tested in anti-
cancer, anti-bacterial, and anti-amoeba bioassays; however, it was found to be inactive in 
all of them. 
2.2.11 Aspergillumarin B 
Aspergillumarin B was first isolated in 2012 in China from a marine-derived 
fungus, Aspergillus sp., which was isolated from a leaf of the mangrove tree Bruguiera 
gymnorrhiza. It was determined that Aspergillumarin B exhibits weak antibacterial 
activity against Staphylococcus aureus and Bacillus subtilis at a concentration of 50 
μg/mL.27 Aspergillumarin B isolated from an unidentified freshwater fungus (G173). It 
was tested and found to be inactive in anti-cancer, anti-bacterial, and anti-amoeba 
bioassays. 
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Figure 4. Secondary Metabolites Isolated and Characterized  
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Figure 4 (cont.). Secondary Metabolites Isolated and Characterized (continued)  
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2.2.12 Berkeleyacetal C 
Berkeleyacetal C was first isolated in 2007 from a deep was Penicillium sp. 
growing in Berkeley Pit Lake in Butte, Montana. It inhibited both MMP-3 and caspase-1 
in the micromolar range and was later accepted in the NCI Developmental Therapeutics 
Program for human cell line screening and tested in the single-dose-response assay. It 
inhibited the growth of non-small-cell lung cancer NCI H460.28 Berkeleyacetal C was 
isolated from an unidentified freshwater fungus (G173). It was tested in anti-cancer, anti-
bacterial, and anti-amoeba bioassays; however, it was found to be inactive in all of them. 
2.2.13 Madisone 
Madisone was first isolated in 2015 from Lindgomyces madisonensis which was 
isolated from a sample collected in a stream in Madison, North Carolina. Madisone was 
tested against Staphylococcus aureus, Escherichia coli, Mycobacterium smegmatis, 
Candida albicans, and Aspergillus niger and has minimal inhibitory concentrations 
greater than 55 μg/mL in all bioassays.29 Madisone was isolated from Lindgomyces 
madisonensis (Lindgomycetaceae) (G416). It was tested in a variety of bioassays and 
found to be inactive in all of them. 
2.2.14 4’-Methoxymadisone 
4’-Methoxymadisone was first isolated as a natural product in 2015 from 
Lindgomyces madisonensis which was isolated from a sample collected in a stream in 
Madison, North Carolina. It was tested against Staphylococcus aureus, Escherichia coli, 
Mycobacterium smegmatis, Candida albicans, and Aspergillus niger and had minimal 
inhibitory concentrations greater than 55 μg/mL in all bioassays.29 4’-Methoxymadisone 
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was isolated from Lindgomyces madisonensis (Lindgomycetaceae) (G416) and 
characterized as inactive in anti-cancer, anti-bacterial, and anti-amoeba bioassays. 
2.2.15 Dimadisone  
Dimadisone was first isolated as a natural product in 2015 from Lindgomyces 
madisonensis which was isolated from a sample collected in a stream in Madison, North 
Carolina. It was not evaluated for antimicrobial activity due to the relative lack of 
material.29 Dimadisone was isolated from Lindgomyces madisonensis 
(Lindgomycetaceae) (G416) and determined to be inactive in anti-cancer, anti-bacterial, 
and anti-amoeba bioassays. 
2.2.16 Monascuspyrone 
Monascuspyrone was first isolated in 2010 in Taiwan from an extract of red mold 
rice fermented with the yellow mutant of the fungus Monascus pilosus.30 
Monascuspyrone was isolated from Microascus nidicola (Microascaceae) (G377) and 
tested in various biological assays. It was inactive in anti-cancer, anti-bacterial, and anti-
amoeba bioassays; however, it was partially active against Staphylococcus aureus with 
52.7% (±1.3) inhibition at 100 μg/mL and 20.4% (±2.6) inhibition at 10 μg/mL (Figure 
5). 
2.2.17 Monascuskaoliaone 
Monascuskaoliaone  was first isolated in 2010 in Taiwan from an extract of 
Monascus kaoliang.31 was isolated from Microascus nidicola (Microascaceae) (G377) 
and tested in various biological assays where it was determined to be inactive against 
cancer, bacteria, and amoeba. 
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2.2.18 Greensporone A 
Greensporone A was first isolated in 2014 from a freshwater aquatic fungus 
Halenospora sp. originating from a stream in Greensboro, North Carolina. It was tested 
against melanoma and colon cancer cell lines yielding IC50 values of 14.1 μM and greater 
than 20 μM, respectively.32 Greensporone A was re-isolated from the same fungus (G87) 
as the original isolation. When tested in anti-cancer, anti-bacterial, and anti-amoeba 
bioassays, it was found to be inactive. 
2.2.19 Greensporone B  
Greensporone B was first isolated in 2014 from a freshwater aquatic fungus 
Halenospora sp. originating from a stream in Greensboro, North Carolina. It was tested 
against melanoma and colon cancer cell lines and found to be inactive against both.32 
Greensporone B was re-isolated from the same fungus (G87) as the original isolation. 
When tested in anti-cancer, anti-bacterial, and anti-amoeba bioassays, it was found to be 
inactive. 
2.2.20 8,9-Dihydrogreensporone A 
8,9-Dihydrogreensporone A was first isolated in 2014 from a freshwater aquatic 
fungus Halenospora sp. originating from a stream in Greensboro, North Carolina. It was 
tested against melanoma and colon cancer cell lines and found to be inactive against 
both.32 8,9-Dihydrogreensporone A was re-isolated from the same fungus (G87) as the 
original isolation. When tested in anti-cancer, anti-bacterial, and anti-amoeba bioassays, 
it was found to be inactive. 
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2.2.21 Dehydroisopenicillide 
Dehydroisopenicillide was first isolated in 1991 in Japan. Dehydroisopenicillide 
was isolated from a Leotiomycetes sp. (G369) and characterized via HRMS and 1H NMR 
in reference to the published values.33 When tested in a variety of bioassays, it was found 
to be inactive. 
 
Table 4. 1H (400 MHz) NMR Data for Dehydroisopenicillide in CDCl3 
 
Position Literature Values δH (J, Hz) Observed δH (J, Hz) 
4’ , 5’ 1.44 (6H, s) 1.43 (6H, s) 
3’ –OH 1.58 (1H, br s)  
9 –Me 2.25 (3H, s) 2.23 (3H, s) 
4 –
OMe 
3.93 (3H, s) 3.92 (3H, s) 
7 5.07 (2H, br s) 5.06 (2H, br s) 
11 –OH 6.09 (1H, br s) 5.96 (1H, br s) 
2’ 6.38 (1H, d, 15.6) 6.38 (1H, d, 16.2) 
8 6.38 (1H, d, 1.8) 6.38 (1H, d, 1.0) 
1’ 6.81 (1H, d, 15.6) 6.80 (1H, d, 16.3) 
10 6.85 (1H, d, 1.8) 6.85 (1H, d, 1.7) 
1 6.86 (1H, d, 8.6) 6.86 (1H, d, 8.5) 
2 7.56 (1H, d, 8.6) 7.57 (1H, d, 8.5) 
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2.2.22 Penicillide 
Penicillide was first isolated in 1974 in Japan from a Penicillium sp.34 Penicillide 
was isolated from a Leotiomycetes sp. (G369) and found to be inactive in anti-cancer, 
anti-bacterial, and anti-amoeba bioassays. 
 
  
 
Figure 5. Percent Inhibition of Staphylococcus aureus at Various Concentrations of 
Various Compounds 
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2.3 Conclusion 
Maintaining supply of secondary metabolites is an ongoing challenge in natural 
products research. There are two options for approaching this challenge: isolate a 
plethora of compound early on or re-isolate later on. The former approach would require 
a researcher to isolate large amounts of compound and the ability to store the material 
where it will not degrade. This storage would allow for further experiments to be done on 
these metabolites later on, such as, semi-synthesis or various biological assays. The risk 
of this approach is degradation of the metabolites while in storage. The latter approach 
would require storage of the fungal culture and regrowth later on. This would take 
advantage of the biological variance of fungi, and this would allow for secondary 
metabolites that were not previously characterized from these fungi to be obtained and 
analyzed. The risk of this approach is fungi not surviving. This project helped show that 
both approaches would yield successful yet different results. 
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CHAPTER III 
PRODUCTION OF GRISEOFULVIN AND DECHLOROGRISEOFULVIN BY 
XYLARIA SPP. 
 
 
3.1 Experimental 
3.1.1 Isolation of Fungal Cultures 
Xylaria flabelliformis (strain G536; previously named Xylaria cubensis) was 
isolated as an endophyte from surface sterilized twigs of paw paw (A. triloba (L.) Dunal, 
Annonaceae) collected from Pfafftown, NC, USA (36º09’58.8”N 80º24’18.6”W) and its 
draft genome was reported recently.12, 35 The additional fungal cultures studied, along 
with G536, are preserved at the University of North Carolina at Greensboro, Department 
of Chemistry and Biochemistry Fungal Culture Collection. 
3.1.2 Cultures in Petri Plate 
The fungi were maintained on potato dextrose agar (PDA; Difco) containing 
antibiotics. To establish the individual monocultures, an agar plug from the leading edge 
of the colony was cut out aseptically and transferred onto Petri plates with PDA 
containing antibiotics. Twelve Petri plates of each fungal strain, 36 plates in total, were 
prepared. The Petri plates were incubated at room temperature (~22ºC). At each time 
point, three biological replicates of each strain were analyzed.
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3.1.3 Extraction of Fungal Cultures 
The fungal growth was ceased by spraying the culture with methanol. The 
contents of the Petri plate were then sliced and transferred into a scintillation vial. The 
vial was then filled with acetone, capped, and left alone for four hours. The solution was 
removed from the vial using a pipette and transferred to a clean, weighed vial and left to 
dry under nitrogen. The dry extract was then treated with a 1:1 ethyl acetate:water 
mixture in order to remove any remaining agar solution. The organic layer was then 
collected and dried. The organic extract was used for the chemical analysis done in this 
experiment. 
3.1.4 Preparation of Griseofulvin and Dechlorogriseofulvin Standards 
Aliquots of each metabolite were weighed and prepared with methanol at a 
concentration of 1.05 mg/mL, then 0.50 mL of each solution were combined in a 1.5 mL 
Eppendorf tube to yield a solution containing 0.525 mg/mL of each compound. Serial 
dilutions were conducted to produce 20 concentrations. 
3.1.5 Preparation of Extracts for LC-MS 
The organic extracts were prepared at a 5 μg/mL concentration, then 200 μL of 
the solution was transferred to an Ansi 96 well – 1 mL plate. 
3.1.6 LC-MS Analysis 
To quantify griseofulvin and dechlorogriseofulvin production, LC-MS analysis 
was conducted in positive ion mode. The mass spectrometer scanned across a mass range 
of m/z 250 to 450 at a resolution of 70,000, and a spray voltage of 4,000. It was coupled 
to an Acquity UPLC system (Waters Corp.), which had a flow rate of 0.3 mL/min and 
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utilized a BEH C18 column (2.1 mm x 50 mm, 1.7 μm) that was operated at 40°C. The 
mobile phase consisted of Fisher Optima LC-MS grade CH3CN-H2O (both acidified with 
0.1% formic acid). The gradient began at 15% CH3CN and linearly increased to 100% 
CH3CN over 8 min. It was held at 100% for 1.5 min before returning to starting 
conditions to re-equilibrate. Each sample was ran in triplicate. The data was analyzed 
using Thermo Xcalibur Qual Browser and  Thermo Xcalibur Quan Browser. The 
quantitation curves for griseofulvin and dechlorogriseofulvin were prepared with a 
quantitation range of 1 ng/mL to 4096 ng/mL and 1 ng/mL to 256 ng/mL, respectively.  
3.2 Results 
Morphological results revealed that G1079 grows the fastest while G755 grows 
the slowest. By week four, the bottom of the plates reveals dark rings beginning to form 
which are common in Xylaria sp. (Figure 6).  
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Figure 6. Pictures of Xylaria spp. Growth Over Four Weeks The first four columns 
display a view of the top of the plate. The last column displays the bottom of a plate that 
had been growing for four weeks. 
 
The Xylaria strains worked with mainly produce two compounds; griseofulvin 
and dechlorogriseofulvin. Griseofulvin is known for its fungistatic properties. The 
metabolite production of each fungal strain at each time point was measured using 
calibration curve. The calibration curves used to measure griseofulvin production (Figure 
7) and dechlorogriseofulvin production (Figure 8) were created using standards and ran in 
triplicate.  
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Figure 7. Calibration Curve Used to Measure the Amount of Griseofulvin Present in 
Extracts 
 
 
 
 
Figure 8. Calibration Curve Used to Measure the Amount of Dechlorogriseofulvin 
Present in Extracts 
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G1079 successfully produced griseofulvin and dechlorogriseofulvin; however, the 
amount produced of both metabolites did not vary over the period of four weeks (Figures 
9 and 10). The griseofulvin production by G536 at week two was not significantly 
different in comparison to the first week, however, week three did show a significant 
difference when compared to week one. Week four is not significantly different than 
week three, which implies that G536 is reaching a maximum production of griseofulvin 
within three weeks of growth (Figure 9). This metabolic trend is not seen when analyzing 
dechlorogriseofulvin production by G536. A significant difference in 
dechlorogriseofulvin production is seen when comparing weeks one and two; however, 
there is no significant difference after week two. Indicating that dechlorogriseofulvin 
production is reaching its maximum within two weeks of growth for G536 (Figure 10). 
G755 reaches its maximum griseofulvin production after four weeks of growth because 
there is a significant difference when comparing weeks one and four. Conversely, there is 
no significant difference amongst the first three weeks (Figure 9). Dechlorogriseofulvin 
biosynthesis in G755 does not follow the same trend, rather there is no significant 
difference over the course of four weeks implying that it reaches its maximum production 
by week one (Figure 10). When comparing the three Xylaria spp. (G1079, G536, G755), 
G536 and G755 produce significantly more griseofulvin and dechlorogriseofulvin than 
G1079 within four weeks of growth. The production of griseofulvin by G536 and G755 is 
not significantly different at their maxima; however, G536 produces a greater abundance 
of dechlorogriseofulvin than G755 (Figure 10). G536 has the highest rate of griseofulvin 
production, whereas G1079 has the lowest production rate. G536 produces 
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dechlorogriseofulvin at a faster rate than both G755 and G1079, which have similar rates 
of production. 
 
 
 
Figure 9. Griseofulvin Production Comparison of the Three Xylaria spp. Strains Over 
Four Weeks 
  
.  
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Figure 10. Dechlorogriseofulvin Production Comparison of the Three Xylaria spp. 
Strains Over Four Weeks 
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A co-culture of Xylaria flabelliformis (G536) and fungal strain G959 was 
analyzed in comparison to the monocultures of each strain. The chromatographic data 
collected on the mass spectrometer indicated the presence of a compound that is not 
present in either of the monocultures. To continue this study, the co-culture will need to 
be scaled-up on solid media. The goal will be to isolate and characterize the compound 
which is not present in either of the monocultures. 
 
 
 
Figure 11. Monocultures of Xylaria flabelliformis (G536) and G959. Co-Culture of 
G536 and G959. Full Base Peak Chromatograms of all of the Cultures.  
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3.3 Conclusion 
These results suggest that G536 is the optimal Xylaria sp. for co-culturing 
experiments since it biosynthesizes more griseofulvin thus creating a more competitive 
environment. Alternatively, G755 may also prove useful in co-culturing experiments 
since it produces similar amounts of griseofulvin but at a slower rate. Allowing for longer 
growth times when needed. There are many fungal strains that can be used in opposition 
of Xylaria sp. in hopes of activating silent biosynthetic gene clusters thus diversifying 
secondary metabolite production. Further analysis of more Xylaria spp. could provide the 
necessary data to optimize co-culturing experimental design.  
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